Chemoinformaics analysis of LABDA-8(17),12-DIENE-15,16-DIAL
| Molecular Weight | 302.458 | nRot | 5 |
| Heavy Atom Molecular Weight | 272.218 | nRig | 15 |
| Exact Molecular Weight | 302.225 | nRing | 2 |
| Solubility: LogS | -4.69 | nHRing | 0 |
| Solubility: LogP | 3.973 | No. of Aliphatic Rings | 2 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 2 |
| Atoms Count | 52 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 22 | No. of Aromatic Carbocycles | 0 |
| nHetero | 2 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 2 |
| No. of Hydrogen atom | 30 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 20 | No. of Saturated Rings | 2 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 2 | No. of Arom Bond | 0 |
| nHA | 2 | APOL | 55.0078 |
| nHD | 0 | BPOL | 31.8322 |
| QED | 0.411 |
| Synth | 4.4 |
| Natural Product Likeliness | 3.348 |
| NR-PPAR-gamma | 0.049 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.854 |
| Pgp-sub | 0 |
| HIA | 0.006 |
| CACO-2 | -4.732 |
| MDCK | 0.0000155 |
| BBB | 0.525 |
| PPB | 0.608034 |
| VDSS | 1.874 |
| FU | 0.242458 |
| CYP1A2-inh | 0.048 |
| CYP1A2-sub | 0.418 |
| CYP2c19-inh | 0.208 |
| CYP2c19-sub | 0.622 |
| CYP2c9-inh | 0.294 |
| CYP2c9-sub | 0.769 |
| CYP2d6-inh | 0.019 |
| CYP2d6-sub | 0.886 |
| CYP3a4-inh | 0.256 |
| CYP3a4-sub | 0.257 |
| CL | 3.583 |
| T12 | 0.14 |
| hERG | 0.007 |
| Ames | 0.025 |
| ROA | 0.011 |
| SkinSen | 0.949 |
| Carcinogencity | 0.279 |
| EI | 0.908 |
| Respiratory | 0.97 |
| NR-Aromatase | 0.098 |
| Antiviral | No |
| Prediction | 0.554978 |